A PubMed search for “DLBCL,” “R-CHOP,” “prognostic,” “marker,” and “prospective” identifies only a few prospective studies, in which biomarkers have been considered (e.g., [15–24]). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.